Clinical trial • Phase III • Dermatology

LEBRIKIZUMAB for Nummular dermatitis

Phase III trial of LEBRIKIZUMAB for Nummular dermatitis.

Overview

Trial Therapeutic Area
Dermatology
Trial Disease
Nummular dermatitis
Trial Stage
Phase III
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
17-11-2025
First CTIS Authorization Date
23-03-2026

Trial design

Randomised, investigational medicinal product: ebglyss 250 mg solution for injection in pre-filled syringe (lebrikizumab; each single-use pfs contains 250 mg in 2 ml, 125 mg/ml). comparator arm: matching placebo (placebo). schedule/dosing frequency not specified in provided data.-controlled Phase III trial across 52 sites in Bulgaria, Italy, Poland and others.

Randomised
Yes
Comparator
Investigational medicinal product: Ebglyss 250 mg solution for injection in pre-filled syringe (lebrikizumab; each single-use PFS contains 250 mg in 2 mL, 125 mg/mL). Comparator arm: matching placebo (Placebo). Schedule/dosing frequency not specified in provided data.
Target Sample Size
241
Trial Duration For Participant
168

Eligibility

Recruits 241 Participants are adults (aged 18 years or more); vulnerable populations were not selected. Written informed consent is required: "1. Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and ability to provide written informed consent in accordance with institutional and regulatory guidelines." No assent process is described..

Pregnancy Exclusion
5. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
Vulnerable Population
Participants are adults (aged 18 years or more); vulnerable populations were not selected. Written informed consent is required: "1. Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and ability to provide written informed consent in accordance with institutional and regulatory guidelines." No assent process is described.

Inclusion criteria

  • {"criterion_text":"- 1. Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and ability to provide written informed consent in accordance with institutional and regulatory guidelines."}
  • {"criterion_text":"- 2. Adult (aged 18 years or more at the time of Screening) diagnosed clinically with NE, as confirmed by the Investigator."}
  • {"criterion_text":"- 3. Presence of NE signs and/or symptoms for at least 6 months prior to Screening."}

Exclusion criteria

  • {"criterion_text":"- 1. Documented history or current presence of moderate-to-severe AD at the Screening visit, or documented diagnosis of moderate-to-severe AD from Screening to Baseline/Day 1 visit (ie, EASI ≥16)."}
  • {"criterion_text":"- 2. Presence of any skin disease, other than NE or mild AD, that could interfere with assessment of the study outcomes, including but not limited to psoriasis and other forms of eczema (dyshidrotic eczema, stasis dermatitis, asteatotic eczema, and neurodermatitis)."}
  • {"criterion_text":"- 3. Presence of any skin manifestations suggestive of psoriasis including but not limited to nail pitting, scalp, palms, soles, or skin folds involvement, as well as personal or family history of psoriasis or psoriatic arthritis."}
  • {"criterion_text":"- 4. History of anaphylaxis as defined by the Sampson criteria."}
  • {"criterion_text":"- 5. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study."}
  • {"criterion_text":"- 6. History of sensitivity and/or allergy to any of the ingredients of the trial medication."}
  • {"criterion_text":"- 7. Participants who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- 1. Percentage of participants achieving endpoint reduction from baseline at Week 24.","definition_or_measurement_approach":"Proportion of participants achieving a reduction from baseline in the specified endpoint at Week 24 (assessment at Week 24 vs baseline)."}

Secondary endpoints

  • {"endpoint_text":"- 1. Percentage of participants with Pruritus NRS ≥4 at baseline achieving a ≥4-point improvement in Pruritus NRS score from baseline at Week 24","definition_or_measurement_approach":"Proportion of participants with baseline Pruritus NRS ≥4 who achieve a ≥4-point improvement in Pruritus NRS score at Week 24 compared with baseline."}
  • {"endpoint_text":"- 2. Absolute change from baseline in DLQI to Week 24.","definition_or_measurement_approach":"Absolute change in Dermatology Life Quality Index (DLQI) score from baseline to Week 24."}

Recruitment

Digital Remote Recruitment
Yes
Planned Sample Size
241
Recruitment Window Months
28
Consent Approach
Written informed consent is required from participants (adults). Inclusion criterion 1 requires ability to provide written informed consent. Subject information and informed consent forms (SIS-ICF) are provided and redacted for multiple languages (documents L1_BG, L1_IT, L1_DE, L1_ES, L1_PL etc.), indicating ICFs available in Bulgarian, Italian, German, Spanish and Polish. No assent process described.

Methods

  • HCP letters (country-specific K2_*_Recruitment Material_HCP Letter documents) — targeted to healthcare professionals to inform about trial (documents available for BG, IT, PL, DE, ES).
  • Posters and brochures (K2_*_Recruitment Material_Poster / Brochure) — site posters/brochures for patient recruitment (country-specific: BG, IT, PL, DE, ES).
  • Web banner ads (K2_*_Recruitment Material_Web Banner Ads) — digital advertising via web banners (country-specific).
  • Facebook Ads (K2_*_Recruitment Material_Facebook Ads) — social media advertising to reach potential participants (country-specific).
  • HCP factsheets (K2_*_Recruitment Material_HCP Factsheet) — informational factsheets for clinicians (country-specific).
  • SIGAL SMS recruitment text blocks (K2_DE_Recruitment Material_SIGAL SMS recruitment text blocks) — SMS-based recruitment in Germany.
  • Recruitment procedures/K1 documents (K1_*_Recruitment Procedure) — country-specific recruitment procedure documents describing local recruitment workflows (available for BG, IT, PL, DE).

Geography

Total Number Of Sites
52
Total Number Of Participants
241

Bulgaria

Earliest CTIS Part Ii Submission Date
20-02-2026
Latest Decision Or Authorization Date
30-03-2026
Processing Time Days
38
Number Of Sites
6
Number Of Participants
17

Sites

Site Name
Diagnostic-Consultative Center Alexandrovska EOOD
Department Name
Dermatology and Venereology
Principal Investigator Name
Petyo Brezoev
Principal Investigator Email
drbrezoev@abv.bg
Contact Person Name
Petyo Brezoev
Contact Person Email
drbrezoev@abv.bg
Site Name
ASMC IPSMC Skin And Venereal Diseases
Department Name
Dermatology and Venereology
Principal Investigator Name
Ivan Botev
Principal Investigator Email
botev2@yahoo.com
Contact Person Name
Ivan Botev
Contact Person Email
botev2@yahoo.com
Site Name
Diagnostics And Consultancy Center Pulmed EOOD
Department Name
Dermatology and Venereology
Principal Investigator Name
Rumyana Yankova
Principal Investigator Email
Rumyana.yankova@abv.bg
Contact Person Name
Rumyana Yankova
Contact Person Email
Rumyana.yankova@abv.bg
Site Name
Dkc Fokus-5 Lzip OOD
Department Name
Dermatology and Venereology
Principal Investigator Name
Grisha Mateev
Principal Investigator Email
grisha_mateev@yahoo.com
Contact Person Name
Grisha Mateev
Contact Person Email
grisha_mateev@yahoo.com
Site Name
Diagnostic And Consulting Center XXVIII-Sofia EOOD
Department Name
Dermatology and Venereology
Principal Investigator Name
Katya Zaharieva
Principal Investigator Email
zaharieva_doctor@abv.bg
Contact Person Name
Katya Zaharieva
Contact Person Email
zaharieva_doctor@abv.bg
Site Name
Medical Center Femiclinic EOOD
Department Name
Dermatology and Venereology
Principal Investigator Name
Nadya Tosheva
Principal Investigator Email
drtoshevafc@gmail.com
Contact Person Name
Nadya Tosheva
Contact Person Email
drtoshevafc@gmail.com

Italy

Earliest CTIS Part Ii Submission Date
05-03-2026
Latest Decision Or Authorization Date
24-03-2026
Processing Time Days
19
Number Of Sites
3
Number Of Participants
25

Sites

Site Name
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
Department Name
Dermatologia e Venereologia
Principal Investigator Name
Caterina Foti
Principal Investigator Email
caterina.foti@uniba.it
Contact Person Name
Caterina Foti
Contact Person Email
caterina.foti@uniba.it
Site Name
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Department Name
U.O. Dermatologia
Principal Investigator Name
Mariateresa Rossi
Principal Investigator Email
Mariateresa.rossi@unibs.it
Contact Person Name
Mariateresa Rossi
Contact Person Email
Mariateresa.rossi@unibs.it
Site Name
Azienda Unita Locale Socio Sanitaria N 8 Berica
Department Name
Dermatology
Principal Investigator Name
Elena Pezzolo
Principal Investigator Email
elena.pezzolo@aulss8.veneto.it
Contact Person Name
Elena Pezzolo
Contact Person Email
elena.pezzolo@aulss8.veneto.it

Poland

Earliest CTIS Part Ii Submission Date
26-11-2025
Latest Decision Or Authorization Date
15-04-2026
Processing Time Days
140
Number Of Sites
13
Number Of Participants
82

Sites

Site Name
Dermmedica Sp. z o.o.
Department Name
CENTRUM COLUMBUS
Principal Investigator Name
Jolanta Weglowska
Principal Investigator Email
office@dermmedica.pl
Contact Person Name
Jolanta Weglowska
Contact Person Email
office@dermmedica.pl
Site Name
Velocity Nova Sp. z o.o.
Department Name
Velocity Skierniewice
Principal Investigator Name
Witold Urban
Principal Investigator Email
wurban@velocityclinical.com
Contact Person Name
Witold Urban
Contact Person Email
wurban@velocityclinical.com
Site Name
Dermaceum Sp. z o.o.
Department Name
DERMACEUM Centrum Medyczne
Principal Investigator Name
Michal Torz
Principal Investigator Email
m.torz@dermacentrum.pl
Contact Person Name
Michal Torz
Contact Person Email
m.torz@dermacentrum.pl
Site Name
Santa Sp. z o.o.
Department Name
Santa Familia PTG Lodz
Principal Investigator Name
Agnieszka Holdrowicz
Principal Investigator Email
agnieszka.holdrowicz@ptgnetwork.com
Contact Person Name
Agnieszka Holdrowicz
Site Name
Clinical Research Center Sp. z o.o. Medic-R sp.k.
Department Name
Clinical Research Center Sp. z o.o. Medic-R sp.k.
Principal Investigator Name
Magdalena Czarnecka-Operacz
Principal Investigator Email
kontakt@cr-center.pl
Contact Person Name
Magdalena Czarnecka-Operacz
Contact Person Email
kontakt@cr-center.pl
Site Name
Zdybski Med Sp. z o.o.
Department Name
ZDYBSKI MED SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA Zdybski Med KIE
Principal Investigator Name
Jacek Zdybski
Principal Investigator Email
jacek@zdybski.pl
Contact Person Name
Jacek Zdybski
Contact Person Email
jacek@zdybski.pl
Site Name
Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.
Department Name
Centrum Nowoczesnych Terapii "Dobry Lekarz" Spółka z ograniczoną odpowiedzialnością
Principal Investigator Name
Malgorzata Dyczek
Principal Investigator Email
katarzyna.gajda@dobrylekarz.com.pl
Contact Person Name
Malgorzata Dyczek
Site Name
Mcbk s.c. Iwona Czajkowska Anna Podrazka Szczepaniak
Department Name
MCBK
Principal Investigator Name
Joanna Rudowska-Okrasko
Principal Investigator Email
j.okrasko@mcbk.pl
Contact Person Name
Joanna Rudowska-Okrasko
Contact Person Email
j.okrasko@mcbk.pl
Site Name
Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.
Department Name
Twoja Przychodnia PCM
Principal Investigator Name
Leszek Bartoszak
Principal Investigator Email
bartoszak@twojaprzychodnia.com
Contact Person Name
Leszek Bartoszak
Contact Person Email
bartoszak@twojaprzychodnia.com
Site Name
LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska
Principal Investigator Name
Dorota Krasowska
Principal Investigator Email
dor.krasowska@gmail.com
Contact Person Name
Dorota Krasowska
Contact Person Email
dor.krasowska@gmail.com
Site Name
ETG Lublin Sp. z o.o.
Department Name
ETG Lublin
Principal Investigator Name
Anna Glowacka
Principal Investigator Email
a.glowacka@etg-network.com
Contact Person Name
Anna Glowacka
Contact Person Email
a.glowacka@etg-network.com
Site Name
Gyncentrum Sp. z o.o.
Department Name
NZOZ Holsamed-Oddział Libero
Principal Investigator Name
Marcin Zakrzewski
Principal Investigator Email
m.zakrzewski@gyncentrum.pl
Contact Person Name
Marcin Zakrzewski
Contact Person Email
m.zakrzewski@gyncentrum.pl
Site Name
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p.
Department Name
CITYCLINIC PRZYCHODNIA LEKARSKOPSYCHOLOGICZNA MATUSIAK SPOLKA PARTNERSKA
Principal Investigator Name
Jacek Szepietowski
Principal Investigator Email
cityclinic.matusiak@gmail.com
Contact Person Name
Jacek Szepietowski
Contact Person Email
cityclinic.matusiak@gmail.com

Germany

Earliest CTIS Part Ii Submission Date
12-02-2026
Latest Decision Or Authorization Date
13-05-2026
Processing Time Days
90
Number Of Sites
18
Number Of Participants
86

Sites

Site Name
Medical Center - University Of Freiburg
Department Name
Klinik für Dermatologi e und Venerologie
Principal Investigator Name
Killian Eyerich
Principal Investigator Email
haut.studienzentrum@uniklinik-freiburg.de
Contact Person Name
Killian Eyerich
Site Name
Universitaetsklinikum Tuebingen AöR
Department Name
Universitäts-Hautklinik
Principal Investigator Name
Sebastian Volc
Contact Person Name
Sebastian Volc
Site Name
Klinische Forschung Osnabrueck
Principal Investigator Name
Sylvia Pauser
Principal Investigator Email
info@klifos.de
Contact Person Name
Sylvia Pauser
Contact Person Email
info@klifos.de
Site Name
Klinikum Oldenburg AöR
Department Name
Clinic for Dermatologyand Allergology
Principal Investigator Name
Nikolaos Patsinakidis
Contact Person Name
Nikolaos Patsinakidis
Site Name
Thermalsole und Schwefelbad Bentheim GmbH
Department Name
Clinical Trial Center
Principal Investigator Name
Athanasios Tsianakas
Principal Investigator Email
studien-dermatologie@fk-bentheim.de
Contact Person Name
Athanasios Tsianakas
Site Name
Gemeinschaftspraxis Weber/Crainic
Principal Investigator Name
Ridwan Weber
Principal Investigator Email
info@wedermic.de
Contact Person Name
Ridwan Weber
Contact Person Email
info@wedermic.de
Site Name
Klinikum Bielefeld gGmbH
Department Name
Clinic for DermatologyVenerology and Allergology
Principal Investigator Name
Katharina Kreutzer
Contact Person Name
Katharina Kreutzer
Site Name
Studienzentrum Dr. Beate Schwarz
Department Name
Dermatology
Principal Investigator Name
Beate Schwarz
Principal Investigator Email
studie@hautarzt-langenau.de
Contact Person Name
Beate Schwarz
Contact Person Email
studie@hautarzt-langenau.de
Site Name
HzFhS Rossbacher-Spickermann eGbR
Department Name
Dermatologie
Principal Investigator Name
Jens Rossbacher
Principal Investigator Email
studien@hzfh.de
Contact Person Name
Jens Rossbacher
Contact Person Email
studien@hzfh.de
Site Name
Goethe University Frankfurt
Department Name
Klinik für Dermatologie, Venerologie und Allergologie (KDVA), Klinische Forschung
Principal Investigator Name
Andreas Pinter
Principal Investigator Email
andreas.Pinter@unimedizin-ffm.de
Contact Person Name
Andreas Pinter
Site Name
Universitaetsklinikum Schleswig-Holstein AöR (Luebeck)
Department Name
Institute for Inflammation Medicine
Principal Investigator Name
Diamant Thaci
Principal Investigator Email
Diamant.thaci@uksh.de
Contact Person Name
Diamant Thaci
Contact Person Email
Diamant.thaci@uksh.de
Site Name
BAG Drs. med. Quist PartG
Department Name
Not applicable
Principal Investigator Name
Sven Quist
Principal Investigator Email
studie@dermatologie-quist.de
Contact Person Name
Sven Quist
Contact Person Email
studie@dermatologie-quist.de
Site Name
Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR
Department Name
Dermatology
Principal Investigator Name
Michael Sebastian
Principal Investigator Email
m.sebastian@derma-mahlow.de
Contact Person Name
Michael Sebastian
Contact Person Email
m.sebastian@derma-mahlow.de
Site Name
Dermatologikum Hamburg GmbH
Department Name
Not applicable
Principal Investigator Name
Peter Weisenseel
Principal Investigator Email
info@dermatologikum.de
Contact Person Name
Peter Weisenseel
Contact Person Email
info@dermatologikum.de
Site Name
Hautarztpraxis Dr. Med. Matthias Hoffmann
Department Name
Not applicable
Principal Investigator Name
Matthias Hoffmann
Principal Investigator Email
drho@hautarzt-dr-hoffmann.de
Contact Person Name
Matthias Hoffmann
Contact Person Email
drho@hautarzt-dr-hoffmann.de
Site Name
Universitaetsklinikum Schleswig-Holstein AöR (Kiel)
Department Name
Department of Dermatology
Principal Investigator Name
Sascha Gerdes
Principal Investigator Email
sgerdes@dermatology.uni-kiel.de
Contact Person Name
Sascha Gerdes
Site Name
Klinikum Darmstadt GmbH
Department Name
Hautklinik
Principal Investigator Name
Mana zur Bruegge
Principal Investigator Email
hautstudien@mail.klinikum-darmstadt.de
Contact Person Name
Mana zur Bruegge
Site Name
Technische Universitaet Dresden
Department Name
Clinic of Dermatology
Principal Investigator Name
Susanne Abraham
Principal Investigator Email
Susanne.abraham@ukdd.de
Contact Person Name
Susanne Abraham
Contact Person Email
Susanne.abraham@ukdd.de

Spain

Earliest CTIS Part Ii Submission Date
12-02-2026
Latest Decision Or Authorization Date
08-05-2026
Processing Time Days
85
Number Of Sites
12
Number Of Participants
31

Sites

Site Name
Hospital De Manises
Department Name
Dermatology
Principal Investigator Name
Antonio Martorell Calatayud
Principal Investigator Email
martorell_antcal@gva.es
Contact Person Name
Antonio Martorell Calatayud
Contact Person Email
martorell_antcal@gva.es
Site Name
Hospital General De Granollers
Department Name
Dermatology
Principal Investigator Name
Antonio Guilabert Vidal
Principal Investigator Email
guilabert@fphag.org
Contact Person Name
Antonio Guilabert Vidal
Contact Person Email
guilabert@fphag.org
Site Name
Hospital Universitario La Paz
Department Name
Dermatology
Principal Investigator Name
Pedro Herranz Pinto
Principal Investigator Email
pedro.herranz@salud.madrid.org
Contact Person Name
Pedro Herranz Pinto
Contact Person Email
pedro.herranz@salud.madrid.org
Site Name
Hospital Universitario Clinico San Cecilio
Department Name
Dermatology
Principal Investigator Name
Francisco Jose Navarro Trivino
Contact Person Name
Francisco Jose Navarro Trivino
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Dermatology
Principal Investigator Name
Jose Juan Pereyra Rodriguez
Principal Investigator Email
jpereyra@us.es
Contact Person Name
Jose Juan Pereyra Rodriguez
Contact Person Email
jpereyra@us.es
Site Name
Icr Medical S.L.
Department Name
Dermatology
Principal Investigator Name
Alvaro Gonzalez Cantero
Principal Investigator Email
alvarogc261893@hotmail.com
Contact Person Name
Alvaro Gonzalez Cantero
Contact Person Email
alvarogc261893@hotmail.com
Site Name
Hospital Universitario Basurto
Department Name
Dermatology
Principal Investigator Name
Rosa Izu Belloso
Principal Investigator Email
rosamaria.izubelloso@osakidetza.eus
Contact Person Name
Rosa Izu Belloso
Site Name
Hospital Universitario Miguel Servet
Department Name
Dermatology
Principal Investigator Name
Servando Marron Moya
Principal Investigator Email
semarron@aedv.es
Contact Person Name
Servando Marron Moya
Contact Person Email
semarron@aedv.es
Site Name
Accellacare Espana S.L.
Department Name
Dermatology
Principal Investigator Name
Pablo Miguel Fonda Pascual
Principal Investigator Email
pfondap@gmail.com
Contact Person Name
Pablo Miguel Fonda Pascual
Contact Person Email
pfondap@gmail.com
Site Name
Hospital Universitario Ramon Y Cajal
Department Name
Dermatology
Principal Investigator Name
María Bibiana Perez García
Principal Investigator Email
bibianapg1@gmail.com
Contact Person Name
María Bibiana Perez García
Contact Person Email
bibianapg1@gmail.com
Site Name
Hospital Marina Baixa De La Vila Joiosa
Department Name
Dermatology
Principal Investigator Name
Francisco Mataix Diaz
Principal Investigator Email
mataixdiaz@hotmail.com
Contact Person Name
Francisco Mataix Diaz
Contact Person Email
mataixdiaz@hotmail.com
Site Name
Hospital Universitario Reina Sofia
Department Name
Dermatology
Principal Investigator Name
Juan Alberto Ruano Ruiz
Principal Investigator Email
juanruanoruiz@mac.com
Contact Person Name
Juan Alberto Ruano Ruiz
Contact Person Email
juanruanoruiz@mac.com

Sponsor

Primary sponsor

Full Name
Almirall S.A.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Contract research organisations

Name
Icon (Lr) Limited
Responsibilities
codes: 1,10,11,12,13,15 (Imaging, PCO),2,3,4,5,6,8,9

Third parties

  • {"country":"Ireland","full_name":"Icon (Lr) Limited","duties_or_roles":"codes: 1,10,11,12,13,15 (Imaging, PCO),2,3,4,5,6,8,9","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"codes: 6,7","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Q Squared Solutions LLC","duties_or_roles":"codes: 15 (value: PK),4","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Mural Health Technologies Inc.","duties_or_roles":"codes: 15 (value: Patient reimubrsement)","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United Kingdom (Northern Ireland)","full_name":"Almac Clinical Services Limited","duties_or_roles":"codes: 14","organisation_type":"Pharmaceutical company"}
  • {"country":"Belgium","full_name":"ArtiQ","duties_or_roles":"codes: 6,7","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Veeva Systems Inc.","duties_or_roles":"codes: 6,7","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Bioclinica Inc.","duties_or_roles":"codes: 6,7","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Fulgent Genetics Inc.","duties_or_roles":"codes: 15 (value: Biomarker testing and storage)","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"Germany","full_name":"eResearchTechnology GmbH","duties_or_roles":"codes: 6,7","organisation_type":"Pharmaceutical company"}
  • {"country":"China","full_name":"Bioclinica Shanghai Co. Ltd.","duties_or_roles":"codes: 6,7","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Labcorp Early Development Laboratories Inc.","duties_or_roles":"codes: 15 (value: PK testing and storage),4","organisation_type":"Pharmaceutical company"}
  • {"country":"Germany","full_name":"BioClinica GmbH","duties_or_roles":"codes: 6,7","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Exco Intouch Limited","duties_or_roles":"codes: 6,7","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Precision For Medicine (UK) Limited","duties_or_roles":"codes: 15 (value: Skin biopsy testing and storage),4","organisation_type":"Pharmaceutical company"}

Investigational products

Investigational Product Name
Ebglyss 250 mg solution for injection in pre-filled syringe
Active Substance
LEBRIKIZUMAB
Modality
Monoclonal antibody
Routes Of Administration
SUBCUTANEOUS INJECTION
Route
Subcutaneous injection
Authorisation Status
Marketing authorisation EU/1/23/1765/001 (prodAuthStatus 2)
Starting Dose
250 mg (each single-use pre-filled syringe contains 250 mg in 2 mL; 125 mg/mL)
Investigational Product Name
Placebo
Modality
Other

Related trials

Other published trials that may interest you.